logo
Plus   Neg
Share
Email

Dynavax, Medigen Collaborate To Develop Adjuvanted COVID-19 Vaccine Candidate

Dynavax Technologies Corp. (DVAX) and Medigen Vaccine Biologics Corp. (MVC) have collaborated to develop an adjuvanted vaccine candidate to protect against COVID-19.

They will evaluate the combination of MVC's stable prefusion form of the SARS-CoV2 recombinant spike protein with Dynavax's advanced adjuvant CpG 1018, the adjuvant contained in Dynavax's U.S. FDA-approved adult hepatitis B vaccine.

"In preclinical testing, the combination of Dynavax's proven adjuvant with our recombinant spike protein vaccine candidate generated strong virus neutralizing antibody responses and cellular immunity. These results support advancing evaluation of the combination into Phase 1 human testing, which we expect to begin in September of this year," said Charles Chen, Chief Executive Officer of Medigen.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT